RESUMO
Pegylated liposomal doxorubicin (PLD) is a drug whose use is increasingly common. It has been associated with a lower rate of haematologic and cardiac side effects than its nonencapsulated form. However, mucocutaneous toxicity is quite frequent and can be severe. Here we provide a case report of a patient who developed an intertrigolike eruption during treatment with PLD (AU)
Assuntos
Humanos , Feminino , Adulto , Antineoplásicos/efeitos adversos , Doxorrubicina/análogos & derivados , Toxidermias/complicações , Toxidermias/patologia , Intertrigo/induzido quimicamente , Intertrigo/patologia , Polietilenoglicóis/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/etiologia , Doxorrubicina/administração & dosagem , Doxorrubicina/efeitos adversos , Metástase Neoplásica , Recidiva Local de Neoplasia/complicações , Estadiamento de Neoplasias , Polietilenoglicóis/administração & dosagemRESUMO
Los pacientes con neutropenia febril constituyen una población heterogénea. La tendencia actual dela mayoría de los grupos de trabajo consiste en tratar de ofrecer un tratamiento individualizado adaptadoal riesgo de complicaciones. El aspecto más crítico se basa en encontrar las variables adecuadas paraseleccionar a los enfermos de bajo riesgo. Desafortunadamente, los sistemas pronósticos más utilizadospresentan una tasa de errores que se puede considerar inaceptable. Este estudio pretende analizartodos los factores pronósticos implicados en la confección de un algoritmo de tratamiento adaptadoal riesgo, que incluya el manejo ambulatorio. Los factores pronósticos evaluados comprenden lossistemas clásicos de Talcott y Mascc, cuya utilidad pronóstica puede resultar controvertida. Además seanalizan los fundamentos clínicos y microbiológicos de la neutropenia febril, y se propone la integraciónde todos estos datos, para conseguir una mayor fiabilidad en la evaluación de los pacientes
Patients with febrile neutropenia are a heterogeneous population. The current tendency of themajority of specialists consists in giving an individual treatment adapted to the risk of complications.The critical aspect is to find suitable variables to select the low risk patients. Unfortunately, the mostcommon prognostic systems have an unacceptable rate of error. The purpose of this study is to analyzeall the significant prognostic factors when making an algorithm based on risk factors. The prognosticutility of Talcott and Mascc systems is controversial. Therefore, we propose to integrate the clinical,laboratory and microbiological data in the prognostic schedule
Assuntos
Humanos , Neutropenia/epidemiologia , Risco Ajustado/métodos , Febre de Causa Desconhecida/epidemiologia , Prognóstico , Leucemia/complicações , Biomarcadores Tumorais/análise , Fatores de Risco , Neoplasias/complicaçõesRESUMO
In the near future molecular biology will permit selection of patients with bladder cancer who can benefit more from radiotherapy and chemotherapy. There will also be an increase in the response rate due to the possibility of regulating the genes responsible for cellular radiosensitivity.
